Dirui Industrial Co.,Ltd. (300396.SZ)
CNY 13.0
(1.17%)
CNY 13.0
(1.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.26 Billion CNY | 25.58% |
| 2022 | 1 Billion CNY | 101.38% |
| 2021 | 499.27 Million CNY | 35.32% |
| 2020 | 368.94 Million CNY | 12.64% |
| 2019 | 327.53 Million CNY | -23.23% |
| 2018 | 426.61 Million CNY | -2.3% |
| 2017 | 436.66 Million CNY | -9.46% |
| 2016 | 482.29 Million CNY | 0.27% |
| 2015 | 480.99 Million CNY | 278.99% |
| 2014 | 126.91 Million CNY | -13.63% |
| 2013 | 146.93 Million CNY | -6.41% |
| 2012 | 156.99 Million CNY | 16.94% |
| 2011 | 134.25 Million CNY | 135.21% |
| 2010 | 57.07 Million CNY | -21.42% |
| 2009 | 72.63 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.09 Billion CNY | -13.57% |
| 2024 Q3 | 974.55 Million CNY | 1.84% |
| 2024 Q2 | 956.91 Million CNY | -12.31% |
| 2023 Q4 | 1.26 Billion CNY | 23.02% |
| 2023 Q3 | 1.02 Billion CNY | 3.92% |
| 2023 FY | 1.26 Billion CNY | 25.58% |
| 2023 Q1 | 991.92 Million CNY | -1.34% |
| 2023 Q2 | 987.67 Million CNY | -0.43% |
| 2022 FY | 1 Billion CNY | 101.38% |
| 2022 Q1 | 469.93 Million CNY | -5.88% |
| 2022 Q4 | 1 Billion CNY | 21.77% |
| 2022 Q3 | 825.7 Million CNY | 24.42% |
| 2022 Q2 | 663.63 Million CNY | 41.22% |
| 2021 FY | 499.27 Million CNY | 35.32% |
| 2021 Q1 | 345.77 Million CNY | -6.28% |
| 2021 Q2 | 430.55 Million CNY | 24.52% |
| 2021 Q3 | 453.08 Million CNY | 5.23% |
| 2021 Q4 | 499.27 Million CNY | 10.2% |
| 2020 Q2 | 573.67 Million CNY | 62.63% |
| 2020 Q3 | 417.66 Million CNY | -27.19% |
| 2020 FY | 368.94 Million CNY | 12.64% |
| 2020 Q1 | 352.74 Million CNY | 7.7% |
| 2020 Q4 | 368.94 Million CNY | -11.66% |
| 2019 FY | 327.53 Million CNY | -23.23% |
| 2019 Q4 | 327.53 Million CNY | -10.4% |
| 2019 Q3 | 365.53 Million CNY | 4.28% |
| 2019 Q2 | 350.54 Million CNY | -0.67% |
| 2019 Q1 | 352.91 Million CNY | -17.27% |
| 2018 Q1 | 377.99 Million CNY | -13.44% |
| 2018 FY | 426.61 Million CNY | -2.3% |
| 2018 Q4 | 426.61 Million CNY | 1.11% |
| 2018 Q3 | 421.94 Million CNY | 9.6% |
| 2018 Q2 | 384.98 Million CNY | 1.85% |
| 2017 Q3 | 374.8 Million CNY | 0.28% |
| 2017 Q4 | 436.66 Million CNY | 16.5% |
| 2017 FY | 436.66 Million CNY | -9.46% |
| 2017 Q1 | 347.15 Million CNY | -28.02% |
| 2017 Q2 | 373.75 Million CNY | 7.66% |
| 2016 Q1 | 497.26 Million CNY | 3.38% |
| 2016 FY | 482.29 Million CNY | 0.27% |
| 2016 Q4 | 482.29 Million CNY | -0.24% |
| 2016 Q3 | 483.46 Million CNY | -2.73% |
| 2016 Q2 | 497.03 Million CNY | -0.05% |
| 2015 Q4 | 480.99 Million CNY | -0.17% |
| 2015 Q2 | 127.96 Million CNY | 15.19% |
| 2015 Q1 | 111.08 Million CNY | -12.47% |
| 2015 FY | 480.99 Million CNY | 278.99% |
| 2015 Q3 | 481.8 Million CNY | 276.51% |
| 2014 Q2 | 125.77 Million CNY | 0.0% |
| 2014 Q1 | - CNY | -100.0% |
| 2014 FY | 126.91 Million CNY | -13.63% |
| 2014 Q4 | 126.91 Million CNY | 7.8% |
| 2014 Q3 | 117.73 Million CNY | -6.39% |
| 2013 FY | 146.93 Million CNY | -6.41% |
| 2013 Q4 | 146.93 Million CNY | 0.0% |
| 2012 FY | 156.99 Million CNY | 16.94% |
| 2011 FY | 134.25 Million CNY | 135.21% |
| 2010 FY | 57.07 Million CNY | -21.42% |
| 2009 FY | 72.63 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 84.265% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 75.856% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 13.175% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | -63.424% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 16.261% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | -9.119% |
| Guangdong Hybribio Biotech Co.,Ltd. | 615.23 Million CNY | -105.224% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 65.015% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -471.203% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | -25.421% |